Medicare Enrolled
Dr. Natalie Maclean, MD, MSC, FRCPC
Internal Medicine · Encinitas, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Maclean from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Maclean?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Maclean
Dr. Natalie Maclean is an internal medicine specialist in Encinitas, CA, with 8 years of NPI registration. Based on federal Medicare data, Dr. Maclean performed 229,255 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Maclean received a total of $22,124 from 29 pharmaceutical and/or device companies across 401 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Maclean is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 8 years of NPI registration
▲ Top 0% volume in CA
$22,124 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗229,255
Medicare services
Top 0% in CA for internal medicine
Not available
Unique patients (not deduplicated)
$8
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Certolizumab injection (Cimzia) An injection of certolizumab pegol administered under the direct supervision of a physician. |
132,001 | $4 | $8 |
| Tocilizumab injection (Actemra) | 42,681 | $5 | $7 |
| Denosumab injection (Prolia/Xgeva) | 22,980 | $18 | $28 |
| Golimumab infusion (Simponi Aria) Administration of golimumab medication directly into a vein. This code specifies the dosage amount of 1 milligram for intravenous delivery. |
10,650 | $11 | $55 |
| Romosozumab injection (Evenity) for osteoporosis | 7,140 | $8 | $18 |
| Abatacept infusion (Orencia) An injection of abatacept administered under the direct supervision of a physician. This code is used for Medicare when the drug is not self-administered. |
6,575 | $34 | $73 |
| Infliximab-abda biosimilar injection, 10 mg This code represents the administration of a 10 mg dose of infliximab-abda, a biosimilar medication. It covers the injection of this specific pharmaceutical product. |
2,920 | $30 | $102 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
1,137 | $64 | $110 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
610 | $103 | $188 |
| Methotrexate sodium, 5 mg | 539 | $0 | $5 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
379 | $8 | $22 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
372 | $113 | $296 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
284 | $149 | $254 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
195 | $73 | $125 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
175 | $25 | $68 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
169 | $0 | $22 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
162 | $10 | $43 |
| New patient office visit, complex (60-74 min) | 55 | $181 | $362 |
| Telephone medical discussion, 21-30 minutes A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone. |
45 | $97 | $175 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
42 | $4 | $8 |
| Joint injection, major joint Removal of fluid from a large joint and/or injection of medication into the joint space. |
33 | $60 | $187 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
28 | $72 | $125 |
| Joint fluid aspiration or injection, small joint Removal of fluid from a small joint or injection of medication into a small joint. |
19 | $43 | $106 |
| Prolonged office E/M service, first 15 minutes This code is used for additional time spent by a physician beyond the maximum required time of a primary office or outpatient evaluation and management service. It is billed in 15-minute increments based on total time spent on the date of the primary service. |
19 | $27 | $75 |
| Methylprednisolone acetate injection, 20 mg A 20 mg injection of methylprednisolone acetate, a corticosteroid medication. This code specifies the drug and dosage administered. |
16 | $4 | $12 |
| Injection, methylprednisolone acetate, 40 mg | 15 | $6 | $12 |
| Methylprednisolone acetate injection, 80 mg An injection of 80 mg of methylprednisolone acetate, a corticosteroid medication. |
14 | $9 | $25 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
7.7% high complexity
91.3% medium
0.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$22,124
Total received (2018-2024)
Avg $3,161/year across 7 years
Top 5% in CA for internal medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
29
Companies
401
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,155
2023
$1,360
2022
$669
2021
$2,336
2020
$7,841
2019
$7,617
2018
$147
Payments by company (2024)
Amgen Inc.
$469
Novartis Pharmaceuticals Corporation
$416
Janssen Biotech, Inc.
$297
GENZYME CORPORATION
$228
Lilly USA, LLC
$183
ABBVIE INC.
$170
Alexion Pharmaceuticals, Inc.
$147
AstraZeneca Pharmaceuticals LP
$100
PFIZER INC.
$86
Genentech USA, Inc.
$41
UCB, Inc.
$19
Top 3 companies account for 54.8% of 2024 payments
All-time payments by company (2018-2024) ›
Regeneron Pharmaceuticals, Inc.
$4,784
Genentech USA, Inc.
$3,899
GENZYME CORPORATION
$2,724
PFIZER INC.
$2,418
Amgen Inc.
$1,828
Horizon Therapeutics plc
$1,707
Novartis Pharmaceuticals Corporation
$1,084
Lilly USA, LLC
$510
Celgene Corporation
$509
Janssen Biotech, Inc.
$415
UCB, Inc.
$290
AstraZeneca Pharmaceuticals LP
$286
SANOFI-AVENTIS U.S. LLC
$243
ABBVIE INC.
$237
Janssen Scientific Affairs, LLC
$217
AbbVie, Inc.
$176
E.R. Squibb & Sons, L.L.C.
$158
Alexion Pharmaceuticals, Inc.
$147
Horizon Pharma plc
$102
GlaxoSmithKline, LLC.
$72
Mallinckrodt Enterprises LLC
$63
Boehringer Ingelheim Pharmaceuticals, Inc.
$62
Actelion Pharmaceuticals US, Inc.
$37
DePuy Synthes Sales Inc.
$36
Radius Health, Inc.
$33
AbbVie Inc.
$30
MEDEXUS PHARMA, INC.
$29
Mallinckrodt Hospital Products Inc.
$20
FIDIA PHARMA USA INC.
$10
Top 3 companies account for 51.6% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AVSOLA · Actemra · BENLYSTA · Bimzelx · COSENTYX · Cimzia · EVENITY · Enbrel · HUMIRA · Humira · Hymovis · ILARIS · KEVZARA · KRYSTEXXA · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OFEV · ORENCIA · ORTHOVISC · Otezla · RAYOS · REMICADE · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SIMPONI · SIMPONI ARIA · SKYRIZI · STELARA · Skyrizi · Sotyktu · TALTZ · TAVNEOS · TREMFYA · Tavneos · Tremfya · Tymlos · ULTOMIRIS · UPTRAVI · XELJANZ
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Internal medicine physicians in nearby ZIP areas
1,567
County median income
$102,285
Nearest hospital to ZIP centroid (approximate)
SCRIPPS MEMORIAL HOSPITAL - ENCINITAS
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Maclean is a mixed practice specialist, with above-average Medicare volume (top 0% in CA).
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Maclean experienced with certolizumab injection (cimzia)?
Based on Medicare claims data, Dr. Maclean performed 132,001 certolizumab injection (cimzia) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Maclean receive payments from pharmaceutical companies?
Yes. Dr. Maclean received a total of $22,124 from 29 companies across 401 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Maclean's costs compare to other internal medicine physicians in Encinitas?
Dr. Maclean's average Medicare payment per service is $8. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Maclean) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Internal Medicine Physicians in Encinitas
Browse internal medicine physicians in Encinitas ranked by procedure volume and transparency data.
Highest volume
Top Internal Medicine Physicians in CA
Internal medicine physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Internal Medicine Physicians in CA
Which CA internal medicine physicians receive the most from drug and device companies.
By company
Regeneron Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Regeneron Pharmaceuticals, Inc.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
By company
GENZYME CORPORATION Payments to Doctors
See all physicians who received payments from GENZYME CORPORATION.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology